Advanced Enzyme Technologies Limited repurchased 55,416 equity shares on September 18, 2026, continuing its open market buyback program. The average acquisition price for the day was ₹288.92.

Emkay Global Financial Services Limited, the Manager to the Buyback, facilitated these transactions exclusively on the National Stock Exchange (NSE). No transactions were reported on the Bombay Stock Exchange (BSE) or Mumbai Stock Exchange (MSEI). There were no closed-out quantities reported for the day.

Daily Buyback Report (Sep 18)

The daily report submitted to the stock exchanges confirms active acquisition for the day.

Buyback Progress Update

As of September 18, 2026, the cumulative number of equity shares bought back stood at 14,08,904. This is an increase from the previous cumulative total of 13,53,488 shares reported as of September 17, 2026. This progress moves the company closer to its initial deployment target of ₹278,800,000, which must be utilized within the first half of the offer period. The total quantity closed out remains at zero.

Buyback Offer Parameters

The buyback targets up to 1,394,000 equity shares, constituting approximately 1.24% of the total paid-up equity share capital as of August 8, 2026. The maximum buyback size is ₹697,000,000, funded entirely from free reserves and internal accruals with no borrowed funds utilized.

The company is required to utilize at least 75% of the Maximum Buyback Size, i.e., ₹522,750,000. Furthermore, at least 40% of the Buyback Size, i.e., ₹278,800,000, must be deployed within the initial half of the Offer Period. The buyback offer is expected to open on or before August 14, 2026, and close no later than November 20, 2026, being sixty-six Working Days from the opening date.

Premium and Market Context

The Maximum Buyback Price of ₹500 carries a substantial premium over recent market benchmarks. On August 8, 2026, the closing market price was ₹324.40 on BSE and ₹324.35 on NSE. The acquisition price of ₹288.92 on September 18 remains well below the maximum ceiling.

This premium reflects management’s confidence in the intrinsic value of the shares and serves as a strong signal to investors regarding the company’s financial health and future prospects.

Capital Structure Impact

If the full Maximum Buyback Size is utilized at the Maximum Buyback Price, the issued, subscribed, and paid-up capital will reduce from 111,976,150 shares to 110,582,150 shares. Promoters and persons in control are excluded from participating in the buyback; their shares will remain frozen at the ISIN level from August 8, 2026, until the buyback closes.

Financial Health and Rationale

The buyback is underpinned by strong financial performance. For Q1 FY27 (ended June 30, 2026), the company reported Revenue from Operations of ₹1,158.57 million and Profit After Tax of ₹223.46 million. In FY2026, Revenue from Operations stood at ₹4,527.66 million with a PAT of ₹1,318.06 million.

The Board confirmed that the company has no subsisting defaults in repayment of deposits, debentures, preference shares, dividends, or term loans. A cash escrow of ₹174,250,000 (25% of Maximum Buyback Size) has been deposited with HDFC Bank Limited. Emkay Global Financial Services Limited serves as the Manager to the Buyback, while MUFG Intime India Private Limited is the Registrar. The process complies with Regulation 5(vii) of the SEBI (Buy-back of Securities) Regulations, 2018, and relevant provisions of the Companies Act, 2013.

Advanced Enzyme Technologies Ltd received revised requests on September 17, 2026, from four promoter group members seeking reclassification to the public category. The move follows an earlier intimation issued by the company on September 5, 2026.

The requests were submitted under Regulation 31A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The applicants include Savita Chandrakumar Rathi, Piyush Chandrakumar Rathi, Advenza Global Limited, and Atharva Green Ecotech LLP.

Shareholding Details

All four entities currently hold nil equity shares in the company. The table below outlines the current shareholding status of the requesting parties.

Regulatory Compliance

Each applicant declared that they do not hold any voting rights or exercise control over the company’s affairs. They also confirmed non-involvement in management, absence of special rights, and no representation on the Board of Directors or as Key Managerial Personnel.

The applicants further stated they are not persons acting in concert with existing promoters, nor are they wilful defaulters or fugitive economic offenders. The reclassification is subject to approval by the Board of Directors and stock exchanges.